Terns Slumps Slightly Despite Record $570M Turnover and Merck Megadeal

Market Snapshot

Terns (TERN) closed with a slight decline of 0.13%, despite leading the market in trading volume on April 2, 2026, with a total turnover of $0.57 billion. The stock opened at $52.79, reflecting a modest upward trajectory at the session's start, but ended the day slightly lower. Terns Pharmaceuticals has a market capitalization of $6.09 billion and a negative price-to-earnings ratio of -51.25. The company's stock has been volatile over the past year, with a 12-month low of $1.87 and a high of $53.19. The 50-day moving average stands at $42.25, and the 200-day average is $30.16, indicating a strong upward trend in recent months.

Key Drivers

The most significant development influencing Terns Pharmaceuticals' stock was the announcement that Merck & Co. (MRK) had agreed to acquire the company for $6.7 billion. This strategic acquisition is expected to impact Merck’s pipeline and broader M&A activity in the biotech sector. Terns’ lead asset, which targets leukemia, is a key driver of the deal, as it aligns with Merck’s focus on oncology and innovative therapies. The acquisition not only reflects confidence in Terns’ pipeline but also signals increased consolidation in the pharmaceutical sector, where companies are increasingly seeking to fast-track development of promising compounds through acquisitions rather than internal R&D.

Institutional interest in Terns’ stock has also surged recently. JPMorgan Chase & Co. increased its stake in the company by 90.6% in the third quarter, acquiring 324,502 additional shares to bring its total holdings to 682,708 shares. This move, which increased JPMorgan’s ownership to 0.76% of Terns Pharmaceuticals, valued at $5.13 million, underscores institutional confidence in the company’s strategic positioning and pipeline. Several other institutional investors also made notable changes, including Polymer Capital Management US LLC and Velan Capital Investment Management LP, which added to their holdings, while Canada Pension Plan Investment Board and Dynamic Technology Lab Private Ltd established new positions during the first and second quarters.

The stock is heavily owned by institutional investors, with 98.26% of shares held by hedge funds and other institutional entities. This level of institutional ownership often indicates a stable investment environment and a reduced influence of retail investors, which can lead to less speculative trading behavior. However, it also means that shifts in institutional sentiment can have a more pronounced effect on the stock price. The recent acquisition by Merck, coupled with increased institutional buying, suggests a growing consensus on the company’s long-term value and the strategic importance of its pipeline in the oncology space.

On the earnings front, Terns Pharmaceuticals reported a loss of $0.24 per share for the first quarter of 2026, which, while a loss, exceeded the expected loss of $0.30 per share by analysts. This beat, albeit narrow, indicates that the company is managing its expenses effectively or that its development programs are progressing as planned. However, analysts forecast that Terns will report a loss of $1.19 per share for the full year, suggesting that profitability remains a distant goal. The company’s focus on preclinical and clinical development of oral therapies for chronic liver diseases and other conditions is still in an early phase, and investors are likely evaluating the potential for long-term growth over short-term profitability.

The mixed analyst ratings also contributed to investor sentiment. While some firms, such as UBS Group, raised their ratings to “strong-buy,” others, including Wall Street Zen and Weiss Ratings, issued “sell” or “hold” ratings, reflecting uncertainty about the stock’s near-term trajectory. The average rating among analysts remains “Hold,” with a consensus price target of $56.30. The divergence in analyst outlook highlights the balancing act investors must perform between the company’s promising pipeline and its current unprofitable status. As Merck’s acquisition moves forward, this could stabilize the stock’s volatility and provide clearer guidance for long-term investors.

Finally, insider activity has also been a point of interest. Insiders, including CEO Amy L. Burroughs, have sold significant portions of their holdings, with Burroughs reducing her stake by 33.92%. While insider selling does not necessarily indicate negative sentiment, it can raise questions about the perceived value of the company’s stock. However, the acquisition by Merck may mitigate these concerns, as it effectively removes the uncertainty surrounding Terns’ independent future. The deal likely offers a premium to shareholders, which could be reflected in the stock’s price stability following the announcement.